MBD2 and adenocarcinoma: In our mouse model, the inflammation can override the Mbd2‐deficient‐dependent anti‐tumour suppression mechanism to such an extent that Apc+/minMbd2−/− mice develop adenocarcinomas, which are rarely, if ever, seen in this model without an inflammatory insult.